RS63575B1 - Postupak za pripremu sintetičkih intermedijera za pripremu tetrahidrohinolinskih derivata - Google Patents
Postupak za pripremu sintetičkih intermedijera za pripremu tetrahidrohinolinskih derivataInfo
- Publication number
- RS63575B1 RS63575B1 RS20220810A RSP20220810A RS63575B1 RS 63575 B1 RS63575 B1 RS 63575B1 RS 20220810 A RS20220810 A RS 20220810A RS P20220810 A RSP20220810 A RS P20220810A RS 63575 B1 RS63575 B1 RS 63575B1
- Authority
- RS
- Serbia
- Prior art keywords
- formula
- compound
- acid
- preparation
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2014050556 | 2014-08-12 | ||
| PCT/NL2015/050555 WO2016024858A1 (en) | 2014-08-12 | 2015-07-29 | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives |
| EP15767345.0A EP3180314B1 (en) | 2014-08-12 | 2015-07-29 | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS63575B1 true RS63575B1 (sr) | 2022-10-31 |
Family
ID=51429345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220810A RS63575B1 (sr) | 2014-08-12 | 2015-07-29 | Postupak za pripremu sintetičkih intermedijera za pripremu tetrahidrohinolinskih derivata |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10112904B2 (enExample) |
| EP (2) | EP4083022A1 (enExample) |
| JP (1) | JP6670310B2 (enExample) |
| KR (1) | KR102572626B1 (enExample) |
| CN (1) | CN107108558B (enExample) |
| AR (1) | AR101509A1 (enExample) |
| AU (1) | AU2015302407B2 (enExample) |
| BR (1) | BR112017002873B1 (enExample) |
| CA (1) | CA2958040C (enExample) |
| CL (1) | CL2017000367A1 (enExample) |
| DK (1) | DK3180314T3 (enExample) |
| EA (1) | EA034357B1 (enExample) |
| ES (1) | ES2926775T3 (enExample) |
| HR (1) | HRP20221061T1 (enExample) |
| HU (1) | HUE059947T2 (enExample) |
| IL (1) | IL250525B (enExample) |
| LT (1) | LT3180314T (enExample) |
| MA (1) | MA40378B1 (enExample) |
| MX (1) | MX367908B (enExample) |
| PL (1) | PL3180314T3 (enExample) |
| PT (1) | PT3180314T (enExample) |
| RS (1) | RS63575B1 (enExample) |
| SG (1) | SG11201701077XA (enExample) |
| SI (1) | SI3180314T1 (enExample) |
| SM (1) | SMT202200385T1 (enExample) |
| TW (1) | TWI691490B (enExample) |
| WO (1) | WO2016024858A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT4125911T (lt) | 2021-03-05 | 2024-08-12 | Newamsterdam Pharma B.V. | Obicetrapibas demencijų gydymui |
| KR20240040767A (ko) | 2021-07-26 | 2024-03-28 | 뉴암스테르담 파마 비.브이. | His 저감반응자의 치료 |
| JP2025501336A (ja) | 2021-12-30 | 2025-01-17 | ニューアムステルダム ファーマ ベー．フェー． | オビセトラピブとｓｇｌｔ２阻害剤との組み合わせ |
| PE20251749A1 (es) | 2022-07-05 | 2025-07-09 | Newamsterdam Pharma B V | Sales de obicetrapib y procesos para su fabricacion y productos intermedios de estos |
| WO2024042061A1 (en) | 2022-08-22 | 2024-02-29 | Newamsterdam Pharma B.V. | Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions |
| WO2024165395A1 (en) | 2023-02-07 | 2024-08-15 | Newamsterdam Pharma B.V. | Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions |
| WO2025059594A1 (en) | 2023-09-15 | 2025-03-20 | Newamsterdam Pharma B.V. | METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH) |
| WO2025093129A1 (en) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
| WO2025093436A1 (en) | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
| WO2025146262A1 (en) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Obicetrapib for use in the treatment of hemoglobinopathies |
| WO2025146415A1 (en) | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Improvement in atherosclerotic plaque characteristics with obicetrapib |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| PL366584A1 (en) * | 2001-04-30 | 2005-02-07 | Pfizer Products Inc. | Compounds useful as intermediates |
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| CN101466679A (zh) * | 2006-03-30 | 2009-06-24 | 田边三菱制药株式会社 | 制备四氢喹啉衍生物的方法 |
| UY30244A1 (es) * | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
-
2015
- 2015-07-29 KR KR1020177006422A patent/KR102572626B1/ko active Active
- 2015-07-29 SI SI201531874T patent/SI3180314T1/sl unknown
- 2015-07-29 EP EP22179712.9A patent/EP4083022A1/en active Pending
- 2015-07-29 PL PL15767345.0T patent/PL3180314T3/pl unknown
- 2015-07-29 DK DK15767345.0T patent/DK3180314T3/da active
- 2015-07-29 BR BR112017002873-5A patent/BR112017002873B1/pt active IP Right Grant
- 2015-07-29 EA EA201790364A patent/EA034357B1/ru active IP Right Revival
- 2015-07-29 EP EP15767345.0A patent/EP3180314B1/en active Active
- 2015-07-29 AU AU2015302407A patent/AU2015302407B2/en active Active
- 2015-07-29 HR HRP20221061TT patent/HRP20221061T1/hr unknown
- 2015-07-29 HU HUE15767345A patent/HUE059947T2/hu unknown
- 2015-07-29 SM SM20220385T patent/SMT202200385T1/it unknown
- 2015-07-29 MX MX2017001930A patent/MX367908B/es active IP Right Grant
- 2015-07-29 JP JP2017528754A patent/JP6670310B2/ja active Active
- 2015-07-29 MA MA40378A patent/MA40378B1/fr unknown
- 2015-07-29 CN CN201580046606.1A patent/CN107108558B/zh active Active
- 2015-07-29 US US15/503,686 patent/US10112904B2/en active Active
- 2015-07-29 PT PT157673450T patent/PT3180314T/pt unknown
- 2015-07-29 CA CA2958040A patent/CA2958040C/en active Active
- 2015-07-29 WO PCT/NL2015/050555 patent/WO2016024858A1/en not_active Ceased
- 2015-07-29 RS RS20220810A patent/RS63575B1/sr unknown
- 2015-07-29 LT LTEPPCT/NL2015/050555T patent/LT3180314T/lt unknown
- 2015-07-29 SG SG11201701077XA patent/SG11201701077XA/en unknown
- 2015-07-29 ES ES15767345T patent/ES2926775T3/es active Active
- 2015-08-10 TW TW104125888A patent/TWI691490B/zh active
- 2015-08-11 AR ARP150102597A patent/AR101509A1/es active IP Right Grant
-
2017
- 2017-02-09 IL IL250525A patent/IL250525B/en active IP Right Grant
- 2017-02-10 CL CL2017000367A patent/CL2017000367A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015302407B2 (en) | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives | |
| EP3366688B1 (en) | Substituted pyrazolopyrimidines as glucocerebrosidase activators | |
| JP6621329B2 (ja) | 新規化合物、それらの合成及びそれらの使用 | |
| AU2013326850B2 (en) | Novel compounds, their preparation and their uses | |
| JPWO2001021206A1 (ja) | ＮＦ−κＢ阻害剤を有効成分とする心筋炎、拡張型心筋症および心不全の予防または治療薬 | |
| EP2185561B1 (fr) | Dérivés de 1,2,3,4-tétrahydropyrrolo(1,2-a)pyrazine-6-carboxamides et de 2,3,4,5-tétrahydropyrrolo(1,2-a)-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique | |
| JP2024072852A (ja) | ３，６－二置換－２－ピリジンアルドキシム骨格 | |
| WO2013186666A1 (en) | Tricyclic compounds as kat ii inhibitors | |
| US10357499B2 (en) | Substituted triazolobenzodiazepines | |
| HK40081593A (en) | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives | |
| KR20250044683A (ko) | 인테그린 억제제 및 다른 작용제와 병용한 이의 용도 | |
| JP2025512815A (ja) | ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物およびその用途 | |
| HK1239687A1 (en) | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives | |
| HK1239687B (zh) | 制备用於制备四氢喹啉衍生物的合成中间体的方法 | |
| CN109280028A (zh) | 喹啉类化合物及其在dpp-4酶抑制剂的应用 | |
| JPH11240882A (ja) | 縮合ピリダジン誘導体、その製造法および用途 |